Dear Editor,

Re. article on "Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study" by Abdo A. Elfiky.

I would like to express my concern about the (online) publication of the above-mentioned article.

My general comment is, that the title may be correct and it sounds promising, but the conclusions are not justified.

In the early HIV days, examples of erroneous mistakes pointed to the fallacious interpretations that could be made based on *molecular docking* studies. Interpretations have been made in this paper that were not generated by real antiviral data, i.e. cell culture data with infected cells. It would be a disservice to the Community worldwide to publish such a paper in a reputable Journal such as *Life Sciences*. Even if only the Abstract were to be screened, there are already clear misnomers, i.e. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir and Tenofovir were hailed as potent drugs against SARS-CoV-2, since they tightly bind to its RdRp. The results suggest the effectiveness of these compounds. This is misleading as tight binding does not mean effectiveness. Effectiveness can only be based on antiviral activity data. A little further in the Abstract, "binding to the RdRp may be used to treat the disease", which, again, is erroneous. Then the Abstract concludes by stating that no toxicity measurements are required for these drugs (mentioned above) since they were previously tested prior to their approval by the FDA. This is certainly not true for IDX-184, Setrobuvir and YAK.

In brief, it would be a mistake for Life Sciences and Elsevier, to publish such a paper. The computer data may be correct, but the conclusions are not. And, finally, SARS-CoV-2 or COVID-19 is not treated by the computer.
